Ray Dalio's DGX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 3,471 shares of Quest Diagnostics Incorporated (DGX) worth $680,247, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in DGX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 208,121 shares. Largest reduction occurred in Q4 2017, reducing 187,561 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Quest Diagnostics Incorporated (DGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Quest Diagnostics Incorporated (DGX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -47 | Reduce 1.34% | 3,471 | $195.98 |
| Q4 2025 | -2,128 | Reduce 37.69% | 3,518 | $173.53 |
| Q3 2025 | +1,875 | Add 49.72% | 5,646 | $190.58 |
| Q2 2025 | -25,497 | Reduce 87.12% | 3,771 | $179.63 |
| Q1 2025 | +7,378 | Add 33.70% | 29,268 | $169.20 |
| Q4 2024 | -66,849 | Reduce 75.33% | 21,890 | $150.86 |
| Q3 2024 | -54,979 | Reduce 38.25% | 88,739 | $155.25 |
| Q2 2024 | -54,083 | Reduce 27.34% | 143,718 | $136.88 |
| Q1 2024 | -3,799 | Reduce 1.88% | 197,801 | $133.11 |
| Q4 2023 | -44,452 | Reduce 18.07% | 201,600 | $137.88 |
| Q3 2023 | +106,639 | Add 76.49% | 246,052 | $121.86 |
| Q2 2023 | -9,108 | Reduce 6.13% | 139,413 | $140.56 |
| Q1 2023 | -46,502 | Reduce 23.84% | 148,521 | $141.48 |
| Q4 2022 | +33,728 | Add 20.91% | 195,023 | $156.44 |
| Q3 2022 | -13,962 | Reduce 7.97% | 161,295 | $122.69 |
| Q2 2022 | +4,220 | Add 2.47% | 175,257 | $132.98 |
| Q1 2022 | +29,631 | Add 20.95% | 171,037 | $136.86 |
| Q4 2021 | +8,794 | Add 6.63% | 141,406 | $173.01 |
| Q3 2021 | +3,800 | Add 2.95% | 132,612 | $145.31 |
| Q2 2021 | +66,636 | Add 107.17% | 128,812 | $131.97 |
| Q1 2021 | -5,567 | Reduce 8.22% | 62,176 | $128.35 |
| Q4 2020 | +34,860 | Add 106.01% | 67,743 | $119.17 |
| Q3 2020 | +28,005 | Add 574.11% | 32,883 | $114.50 |
| Q2 2020 | -2,422 | Reduce 33.18% | 4,878 | $113.98 |
| Q1 2020 | +7,300 | New Buy | 7,300 | $80.27 |
| Q3 2019 | -34,817 | Sold Out | 0 | $0.00 |
| Q2 2019 | -19,541 | Reduce 35.95% | 34,817 | $101.82 |
| Q1 2019 | -87,368 | Reduce 61.65% | 54,358 | $89.92 |
| Q4 2018 | +108,465 | Add 326.10% | 141,726 | $83.27 |
| Q3 2018 | +6,706 | Add 25.25% | 33,261 | $107.90 |
| Q2 2018 | -92,574 | Reduce 77.71% | 26,555 | $109.92 |
| Q1 2018 | +98,569 | Add 479.42% | 119,129 | $100.30 |
| Q4 2017 | -187,561 | Reduce 90.12% | 20,560 | $98.49 |
| Q3 2017 | +208,121 | New Buy | 208,121 | $93.64 |
| Q1 2016 | -64,399 | Sold Out | 0 | $0.00 |
| Q4 2015 | -172,193 | Reduce 72.78% | 64,399 | $71.13 |
| Q3 2015 | +166,203 | Add 236.12% | 236,592 | $61.47 |
| Q2 2015 | -77,699 | Reduce 52.47% | 70,389 | $72.53 |
| Q1 2015 | +94,962 | Add 178.75% | 148,088 | $76.85 |
| Q4 2014 | +37,500 | Add 239.98% | 53,126 | $67.07 |
| Q3 2014 | +2,081 | Add 15.36% | 15,626 | $60.67 |
| Q2 2014 | -65,432 | Reduce 82.85% | 13,545 | $58.69 |
| Q1 2014 | +78,977 | New Buy | 78,977 | $57.92 |
| Q3 2013 | -4,598 | Sold Out | 0 | $0.00 |
| Q2 2013 | +4,598 | Add 0.00% | 4,598 | $60.68 |
Ray Dalio's Quest Diagnostics Incorporated Investment FAQs
Ray Dalio first purchased Quest Diagnostics Incorporated (DGX) in Q2 2013, acquiring 4,598 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Quest Diagnostics Incorporated (DGX) for 45 quarters since Q2 2013.
Ray Dalio's largest addition to Quest Diagnostics Incorporated (DGX) was in Q3 2017, adding 208,121 shares worth $19.49 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 3,471 shares of Quest Diagnostics Incorporated (DGX), valued at approximately $680,247.
As of the Q1 2026 filing, Quest Diagnostics Incorporated (DGX) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Quest Diagnostics Incorporated (DGX) was 246,052 shares, as reported at the end of Q3 2023.